Haematologica

Haematologica www.haematologica.org publishes novel findings in basic, clinical and translational hematology research. Impact Factor (JCR) 7.116 (7th of 76)

Haematologica/The Hematology Journal (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by a non-profit organization, the Ferrata Storti Foundation, and serves the scientific community strictly following the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) recommendations on publication ethics policies for medical journals. Haematologica was founded in 1920 by Adolfo Ferrata

Post-transplant cyclophosphamide for acute lymphoblastic leukemia in earlier and later eras: the outcomes of two retrosp...
27/11/2025

Post-transplant cyclophosphamide for acute lymphoblastic leukemia in earlier and later eras: the outcomes of two retrospective cohorts. The importance of effective pre-transplant therapy. A must-read for those following advances in leukemia treatment.
https://haematologica.org/article/view/12054

Non-Langerhans cell histiocytosis comprises a heterogeneous group of diseases including Erdheim-Chester disease, the xan...
25/11/2025

Non-Langerhans cell histiocytosis comprises a heterogeneous group of diseases including Erdheim-Chester disease, the xanthogranuloma family of lesions, Rosai-Dorfman disease, indeterminate cell histiocytosis, and malignant histiocytic neoplasms. In the present review Hershkovitz-Rokah and colleagues synthesize key advancements in the field and propose a blueprint for future research to address unmet needs.
https://haematologica.org/article/view/haematol.2024.286479

The second review on histiocytic disorders regards major clinical and pathobiological milestones in Langerhans cell hist...
23/11/2025

The second review on histiocytic disorders regards major clinical and pathobiological milestones in Langerhans cell histiocytosis (LCH) reached in the last two decades, with a spotlight on critical, unanswered questions that need to be addressed to further improve the clinical management and outcomes of patients with LCH.
https://haematologica.org/article/view/haematol.2024.286478

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by an excessive but ineffe...
21/11/2025

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by an excessive but ineffective immune response leading to cellular hyperactivation and rampant cytokine secretion and can be subdivided into primary HLH and secondary HLH. In their review paper Meyer and colleagues highlight the major biological and clinical advances surrounding HLH in recent decades.
https://haematologica.org/article/view/haematol.2024.286477

Histiocytic disorders encompass a diverse and rare group of conditions including histiocytic neoplasms such as Langerhan...
19/11/2025

Histiocytic disorders encompass a diverse and rare group of conditions including histiocytic neoplasms such as Langerhan cell histiocytosis (LCH) and non-LCH, and hyperinflammatory diseases like hemophagocytic lymphohistiocytosis (HLH). The Histiocyte Society (https://histiocytesociety.org), founded in 1985, is the scientific organization that has played a pivotal role in advancing the study and treatment of histiocytic disorders. In the review series published in this issue of Haematologica, find a group of articles that highlight the progress and future directions in each of the three main subtypes of histiocytic disorders.
https://haematologica.org/article/view/haematol.2024.286481

When standard therapies fall short, innovation steps in. In this new case study, a patient with POEMS syndrome received ...
17/11/2025

When standard therapies fall short, innovation steps in. In this new case study, a patient with POEMS syndrome received ciltacabtagene autoleucel chimeric antigen receptor T-cell therapy — a treatment rarely explored in this setting.
https://haematologica.org/article/view/12109

Novel immunotherapies can change lives—but sometimes, they open unexpected doors. Read the case of a patient on bispecif...
15/11/2025

Novel immunotherapies can change lives—but sometimes, they open unexpected doors. Read the case of a patient on bispecific antibody therapy who developed two rare opportunistic infections, cytomegalovirus retinitis and chronic salmonellosis. How could this happen? And what does it teach us about immune balance?
https://haematologica.org/article/view/12178

A 67-year-old woman, without a significant past medical history, presented with pain, swelling and erythema of the right...
13/11/2025

A 67-year-old woman, without a significant past medical history, presented with pain, swelling and erythema of the right lower extremity, as well as night sweats, and weight loss of approximately 18 kg over the preceding 5 months. This is an intriguing case of a striking response to EZH2 inhibition in an aggressive hematolymphoid neoplasm with homozygous SMARCB1 loss.
https://haematologica.org/article/view/12133

Clonal myeloid disorders arising in patients with non-Hodgkin lymphoma treated with CD19-directed chimeric antigen recep...
11/11/2025

Clonal myeloid disorders arising in patients with non-Hodgkin lymphoma treated with CD19-directed chimeric antigen receptor T-cell therapies: a new single-center experience.
https://haematologica.org/article/view/12049

The multicenter randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the m...
09/11/2025

The multicenter randomized phase III NHL-004 study compared etoposide, dexamethasone and pegaspargase (ESA) versus the methotrexate, etoposide, dexamethasone and pegaspargase (MESA) regimen, combined with sandwiched radiotherapy, in newly diagnosed early-stage nasal natural killer/T-cell lymphoma: find here long-term outcomes and biomarker analyses.
https://haematologica.org/article/view/12026

Targeting acute lymphoblastic leukemia (ALL) at the metabolic level is a story of success, but so far, it has been restr...
07/11/2025

Targeting acute lymphoblastic leukemia (ALL) at the metabolic level is a story of success, but so far, it has been restricted to asparagine depletion. Tee and colleagues tested a novel therapeutic approach targeting the methionine cycle, sparking new hope for patients with KMT2A-rearranged ALL.
https://haematologica.org/article/view/12034

Indirizzo

Via Giuseppe Belli 4
Pavia
27100

Orario di apertura

Lunedì 09:00 - 18:00
Martedì 09:00 - 18:00
Mercoledì 09:00 - 18:00
Giovedì 09:00 - 18:00
Venerdì 09:00 - 18:00

Telefono

+39038227129

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Haematologica pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta Lo Studio

Invia un messaggio a Haematologica:

Scelte rapide

Promuovere

Condividi

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram